Chronic kidney disease (CKD), a health issue experiencing rapid growth, is projected to become the fifth leading cause of global mortality by 2040. This rapid rise is a consequence of increased survival from a variety of diseases (cancer, cardiovascular disease, diabetes, etc.), an aging population, the lack of reliable early CKD diagnostic tools, the insufficient awareness of CKD within healthcare, a restricted range of treatments to stop CKD progression, and limitations of current kidney replacement therapies (KRTs). With a shared aim to address these concerns, the European Kidney Health Alliance (EKHA) and the American Association of Kidney Patients partnered within the Decade of the KidneyTM framework. The EKHA Work Group 'Breakthrough Innovation' elucidates its rationale and vision, seeking to revolutionize the entrenched innovation paradox on KRT. The concepts of international technological roadmapping and coopetition are examined in the context of leveraging breakthrough KRT technologies, and a map of the kidney innovation playing field is presented, driven by patient advocacy groups.Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with favorable effects on the cardiovascular system and kidneys, specifically exhibiting cardioprotection and renoprotection. However, empirical studies examining SGLT2 inhibitors' impact on diabetic kidney transplant recipients (DKTRs) are scarce.An observational multicenter study examined the usefulness and tolerability of SGLT2 inhibitors among individuals with diabetes mellitus. Within six months of commencing SGLT2i treatment, adverse effects represented the primary outcome.Of the 339 DKTRs who were treated, 26% suffered from adverse effects, with urinary tract infections (UTIs) being the most frequent at 14%. In 10% of instances, the use of SGLT2 inhibitors was halted, predominantly because of urinary tract infections. Prior urinary tract infections (UTIs) within six months before starting SGLT2i use were significantly linked to a higher risk of developing a UTI, with an odds ratio (OR) of 790 (confidence interval [CI]: 363-1721). Female sex was also identified as a risk factor, with an odds ratio of 246 (CI: 119-503). In a follow-up analysis of the subgroups, the rate of UTI was found to be equivalent in DKTRs who received SGLT2i for 12 months and non-DKTRs (179% versus 167%). Patients exhibited substantial reductions in body weight (-222 kg, 95% CI -279 to -165 kg) and several other parameters between baseline and 6 months. Blood pressure, fasting glycaemia, haemoglobin A1c levels (-0.36% [95% CI -0.51 to -0.21]), serum uric acid (-0.44 mg/dL [95% CI -0.60 to -0.28]), and the urinary protein-to-creatinine ratio all showed decreases. In contrast, serum magnesium levels increased (+0.15 mg/dL [95% CI 0.11-0.18]) and hemoglobin levels rose significantly (+0.44 g/dL [95% CI 0.28-0.58]). Treatment outcomes observed in participants over a 12-month period were consistent and enduring.In kidney transplant cases, the utilization of SGLT2 inhibitors provides beneficial outcomes in controlling blood glucose, managing weight, regulating blood pressure, treating anemia, decreasing proteinuria, normalizing serum uric acid levels, and maintaining optimal magnesium levels. The most common adverse outcome was a urinary tract infection (UTI). In our view, these agents should be prescribed cautiously to female DKTRs and those who have previously experienced urinary tract infections.SGLT2 inhibitors, after kidney transplantation, yield positive effects in controlling blood sugar, managing body weight, regulating blood pressure, mitigating anemia, reducing urinary protein levels, and influencing serum levels of uric acid and magnesium. In terms of adverse effects, UTI held the top spot for frequency. These agents, according to our findings, warrant cautious prescription practices for female DKTRs and patients with prior urinary tract infections.Adult-onset autosomal dominant polycystic kidney disease (ADPKD) is common, but children affected by the condition frequently experience substantial illness. This study sought to analyze the clinical characteristics of ADPKD in young adults.The Spanish ADPKD registry (REPQRAD) reviewed 346 young adults (18-30 years of age), part of a larger group of 2521 patients, focusing on family history, hypertension, albuminuria, estimated glomerular filtration rate (eGFR), and imaging test results. A literature review examined case series of hypertension involving more than fifty young adults (below 30 years) with ADPKD.25.24 years (SD 3.72) was the average age found among this young adult group. Patients diagnosed with hypertension had a mean age of 2115 years (standard deviation 462), while the average age within the broader REPQRAD population was 376 years. Hypertension's prevalence reached 2803%, escalating with advancing age, exhibiting a substantial increase from 168% in the 18-24 age group to 368% in the 25-30 age bracket. Although women exhibited a lower rate of hypertension, the age of onset, 21 years, was identical for both men and women. The mean eGFR was calculated as 108 mL/min/1.73 m², exhibiting a standard deviation of 21.Liver cysts were present in 380% of the examined cases, and 345% of those cases also showed intracranial aneurysms. Multivariate analyses revealed hematuria episodes and kidney length as independent predictors of hypertension, exhibiting an area under the curve of 0.75. Twenty to forty percent of 22 pediatric cohorts exhibited hypertension, but there were no published reports addressing hypertension in young adult patients with ADPKD.ADPKD morbidity affects young adults to a degree that cannot be disregarded. A thorough assessment of young adults vulnerable to ADPKD is essential for early detection and management of hypertension.ADPKD-related health issues are notably prevalent among young adults. A thorough assessment is imperative for the early detection and treatment of hypertension in young adults susceptible to ADPKD.Optimal patient care is anchored in clinical practice guidelines, with a strong focus on shared decision-making. Unfortunately, the guidelines and interventions intended to support their implementation often disregard the specific requirements of ethnic minority populations, leading to disparities in chronic kidney disease (CKD) prevalence and outcomes. This review seeks to delineate the interventions available to bolster decision-making, self-management, and/or health literacy for ethnic minority individuals diagnosed with CKD, to detail the processes of intervention development and/or adaptation, and to analyze the consequential effect on patient outcomes. Study data extraction and bias assessment were conducted independently by two reviewers, after a search of six databases (MEDLINE, PsychINFO, Scopus, EMBASE, CINAHL, InformitOnline). Six nations, encompassing nine distinct ethnic minority groups, were the focus of twelve studies, each involving 291 participants. Intervention strategies utilized the following approaches: (i) in-person education and skill building (three studies, n = 160), (ii) provision of educational materials to patients (two studies, sample size undisclosed), (iii) engagement of Cultural Health Liaison Officers (six studies, n = 106), and (iv) expansion of healthcare access (three studies, n = 25). There was a constrained overview of cultural targeting and tailoring methods. In cases where written materials required translation from English, the process adhered strictly to verbatim translation, without integrating any cultural modifications. Limited research explores community-based research approaches, focusing on interventions adaptable without significant literacy demands (e.g.). aminoacid-transport Infographics, photographs, and interviews with local community members were integrated with the involvement of a Cultural Health Liaison Officer in the intervention's framework. A review of community-based interventions, to determine their impact on clinical and psychosocial outcomes, was not conducted. Interventions conducted within the hospital setting uniformly demonstrated positive outcomes. Routine care was contrasted with the strategies aiming for a decrease in blood pressure, but methodological concerns posed challenges to the study's conclusions.Chronic kidney disease patients, diabetic or not, experience improved cardiovascular and renal outcomes with sodium-glucose cotransporter-2 inhibitors. Literature concerning the safety and efficacy of SGLT2is is lacking in kidney transplant recipients due to their absence from landmark trials. Investigative studies of late have shown SGLT2i usage to be safe in kidney transplant recipients experiencing diabetes, which inspires further research into its potential to lessen cardiovascular complications and renal function decline in kidney allograft recipients.The study's goal is to devise a novel and practical nomogram and risk stratification scheme for accurate prediction of cancer-specific survival (CSS) in early-onset locally advanced rectal cancer (EO-LARC) patients.The SEER database yielded 2440 patients, all diagnosed with EO-LARC between 2010 and 2019, for screening. A random sampling from the pool of potentially eligible patients resulted in two cohorts: one for training (N=1708) and the other for validation (N=732). The nomogram's creation and calibration process incorporated diverse approaches, encompassing the coherence index (C-index), receiver operating characteristic (ROC) curves, calibration curves, and decision curves (DCA). Based on the nomogram, a new system for classifying risks was established. To gauge the efficacy of this nomogram relative to the American Joint Committee on Cancer (AJCC) staging system, DCA, net reclassification index (NRI), and integrated discrimination improvement (IDI) were employed as metrics.Seven variables formed part of the model's structure. The training cohort's area under the ROC curve (AUC) at 3, 6, and 9 years stood at 0.766, 0.736, and 0.731, respectively.